tagmokitug + toripalimab (Coherus BioSciences, Inc.)

Tagmokitug + Loqtorzi (toripalimab-tpzi) is an investigational combination immunotherapy regimen being developed by Coherus BioSciences for the treatment of advanced solid tumors, with a primary focus on esophageal cancer. Tagmokitug (formerly CHS-114 or SRF114) is a highly selective, afucosylated cytolytic monoclonal antibody targeting C-C chemokine receptor type 8 (CCR8), which is highly expressed on regulatory T cells (Tregs) within the tumor microenvironment. By binding to CCR8, tagmokitug depletes these immunosuppressive Tregs via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thereby enhancing antitumor immune responses. Loqtorzi (toripalimab) is an approved humanized IgG4 monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor, preventing its interaction with PD-L1 and PD-L2 to restore T-cell-mediated immune responses. The combination is being evaluated in Phase 1b/2a clinical trials (TREGCHECK 101 and TREGCHECK 102) with or without chemotherapy. In November 2026, Coherus announced a strategic shift to prioritize esophageal cancer indications (including esophageal squamous cell carcinoma and esophageal adenocarcinoma) and deprioritize other solid tumor indications such as head and neck squamous cell carcinoma, gastric cancer, and colorectal cancer.